Form 4: Rigel Pharmaceuticals Executive Stock Transaction

EVP and Chief Commercial Officer David A. Santos disposed of 874 shares of Rigel Pharmaceuticals common stock to cover tax obligations.

Summary

• David A. Santos, EVP and Chief Commercial Officer of Rigel Pharmaceuticals, Inc., reported the disposition of 874 shares of common stock.
• The transaction occurred on June 1, 2026, at a price of $29.86 per share.
• The disposition was executed to satisfy tax withholding obligations related to the vesting of equity awards.
• Following this transaction, the reporting person maintains beneficial ownership of 61,996 shares of Rigel Pharmaceuticals common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it represents a routine tax-related transaction rather than a change in executive sentiment or company strategy.

Positives

• The transaction was a routine administrative action related to tax withholding rather than a discretionary sale of shares.

Negatives

• The reporting person reduced their total equity stake in the company by 874 shares.

Risks

• None identified; this is a standard regulatory disclosure for executive compensation tax compliance.

Future Outlook

No forward-looking guidance or strategic outlook was provided in this regulatory filing.

Industry Context

StockSavvy.ai notes that this filing is a standard administrative disclosure common in the biotechnology sector, where executive compensation packages frequently include equity grants that trigger tax withholding events upon vesting.

Comparison to Industry Standards

• The transaction aligns with standard corporate governance practices for executive equity management.
• The use of 'sell-to-cover' transactions is a common industry practice for managing tax liabilities associated with restricted stock unit (RSU) vesting.

Stakeholder Impact

• Minimal impact on shareholders as the transaction was a non-discretionary tax withholding event.

Next Steps

• No future actions or milestones were disclosed in this filing.

Key Dates

Keywords

Rigel Pharmaceuticals, RIGL, Form 4, Insider Trading, Executive Compensation, SEC Filing